Clinical Appearance and Diagnosis of Heparin Induced Thrombocytopenia
Journal of Biomedical Research & Environmental Sciences, Page: 466-471
2021
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Heparin-İnduced Thrombocytopenia (HIT) [1] is caused by an autoantibody directed against endogenous Platelet Factor 4 (PF4) in complex with heparin. This antibody activates platelets and can cause arterial and venous thrombosis. Although the mortality rate of untreated HIT is determined as 20 percent; With early diagnosis and treatment, mortality rates have been reported to be less than 2 percent [2,3]. The clinical picture and diagnosis of HIT will be discussed here. The management of HIT and the use of heparin and alternative anticoagulants are discussed separately.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know